These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24195468)

  • 41. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
    El Zarif T; Meador CB; Qiu X; Seo JH; Davidsohn MP; Savignano H; Lakshminarayanan G; McClure HM; Canniff J; Fortunato B; Li R; Banwait MK; Semaan K; Eid M; Long H; Hung YP; Mahadevan NR; Barbie DA; Oser MG; Piotrowska Z; Choueiri TK; Baca SC; Hata AN; Freedman ML; Berchuck JE
    Clin Cancer Res; 2024 Sep; 30(17):3798-3811. PubMed ID: 38912901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
    Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
    World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review.
    Li X; Luan X; Zhang M; Wang R; Guo J; Lv J; Qiu W; Zhao S
    Front Immunol; 2024; 15():1439033. PubMed ID: 39234244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
    Liu J; Xia L; Peng Y; Huang YS; Yang ZZ
    Medicine (Baltimore); 2021 Oct; 100(39):e27289. PubMed ID: 34596125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
    Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
    Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
    Ho HL; Kao HL; Yeh YC; Chou TY
    Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
    Xue S; Yu T; Zhang Y; Shan L
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):656-60. PubMed ID: 26483340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
    Fallet V; Ruppert AM; Poulot V; Lacave R; Belmont L; Antoine M; Cadranel J; Wislez M; Lavolé A
    J Thorac Oncol; 2012 Jun; 7(6):1061-3. PubMed ID: 22588159
    [No Abstract]   [Full Text] [Related]  

  • 60. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
    Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
    Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.